Table 1

Clinical assessment, response to infliximab treatment and HMGB1 expression.

Pat

W

Sex

Age (years)

Disease duration (years)

CRP

Medication

DAS28

Clinical response

HMGB1 protein

HMGB1mRNA

MTX

Pred

DAS28

ACR

ES

CG

1

0

F

55

18

107

17.5

5 *

6.71

1.5

1

9

38

6.34

No

0

2

1.5

2

0

F

52

6

14

7.5

7.5

6.00

1.5

1.5

9

15

4.43

Mod

20

1

0.5

0

3

0

F

58

2

46

10

7.91

3

4

9

25

5.41

Mod

50

1

1.5

0

4

0

F

57

4

7

10

4.94

2

2

9

34

4.41

No

20

2

2

Up

5

0

M

56

7

44

15

5.95

2

2.5

9

7

2.90

G

70

3.5

3

6

0

F

69

1

69

15

5

7.39

2

3

9

7

1.79

G

70

1.5

2.5

Up

7

0

F

66

14

34

10

5.64

2

2

9

16

4.73

Mod

0

1

0.5

Down

8

0

F

66

10

18

12.5

4.83

3.5

4

9

19

4.23

Mod

0

0.5

2

Down

9

0

M

25

0.6

26

17.5

7.5

5.62

.5

3

9

25

3.91

Mod

20

3

4

* Patient 1 also received 150 mg/day cyclosporine before and during the study period.Pat = Patient, W = week, CRP = C-reactive protein, MTX = Methotrexate (mg/week), Pred = Prednisone (mg/day), DAS28 = disease activity score calculated on 28 joints, ACR = American College of Rheumatology, HMGB1 = High-mobility group box chromosomal protein 1, ES = Erik Sundberg, CG = Cecilia Grundtman, F = Female, M = Male, No = Non, Mod = Moderate, G = Good.

Sundberg et al. Arthritis Research & Therapy 2008 10:R33   doi:10.1186/ar2387